title: Reply to S. Girnius et al.
authors.forename: Giovanni
authors.initials: G
authors.lastname: Palladini
authors.forename: Angela
authors.initials: A
authors.lastname: Dispenzieri
authors.forename: Morie
authors.initials: M
authors.lastname: Gertz
authors.forename: Shaji
authors.initials: S
authors.lastname: Kumar
authors.forename: Ashutosh
authors.initials: A
authors.lastname: Wechalekar
authors.forename: Philip N
authors.initials: PN
authors.lastname: Hawkins
authors.forename: Stefan
authors.initials: S
authors.lastname: Schönland
authors.forename: Ute
authors.initials: U
authors.lastname: Hegenbart
authors.forename: Raymond
authors.initials: R
authors.lastname: Comenzo
authors.forename: Efstathios
authors.initials: E
authors.lastname: Kastritis
authors.forename: Meletios A
authors.initials: MA
authors.lastname: Dimopoulos
authors.forename: Arnaud
authors.initials: A
authors.lastname: Jaccard
authors.forename: Catherine
authors.initials: C
authors.lastname: Klersy
authors.forename: Giampaolo
authors.initials: G
authors.lastname: Merlini
mesh_terms: D000686:Amyloidosis / Q000097:blood* / Q000628:therapy*; D005260:Female; D006801:Humans; D007147:Immunoglobulin Light Chains / Q000097:blood*; D008297:Male
chemical_list: D007147:Immunoglobulin Light Chains